Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

William Bacon

Physician Assistant, Medical Santa Fe, NM Physician Assistant

NPI 1730181942 CMS profile 10632949

1650 Hospital Dr Ste 500, Santa Fe, NM 87505

Open in the dashboard

General payments

$6,188

330 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Bacon of Santa Fe, NM is reported in the CMS Open Payments database as having received $6,188 across 330 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $481 12
2024 General $1,417 71
2023 General $1,226 69
2022 General $1,243 70
2021 General $1,821 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Bacon
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to William Bacon were reported at $481. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year William Bacon Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,821 $156 $41–$563 $132
2022 $1,243 $185 $55–$649 $149
2023 $1,226 $199 $58–$717 $160
2024 $1,417 $206 $62–$740 $164
2025 $481 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $622 36 payments
  2. Lilly USA, LLC $523 26 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $516 21 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $458 31 payments
  5. Daiichi Sankyo Inc. $361 24 payments
  6. Novo Nordisk Inc $308 18 payments
  7. Janssen Pharmaceuticals, Inc $278 13 payments
  8. AbbVie, Inc. $265 14 payments
  9. Nestle HealthCare Nutrition Inc. $261 15 payments
  10. Pfizer Inc. $230 13 payments
  11. Other $2,366 119 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,182 329 payments
  2. Education $7 1 payment
Products named General payments · program years 2021–2025
  1. XIFAXAN $458 31 payments
  2. TRULANCE $434 29 payments
  3. INJECTAFER $361 24 payments
  4. BREZTRI $352 19 payments
  5. ZENPEP $347 20 payments
  6. XARELTO $278 13 payments
  7. JARDIANCE $251 12 payments
  8. RYBELSUS $241 14 payments
  9. MOUNJARO $237 13 payments
  10. Ozempic $227 13 payments
  11. Other $4,226 218 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 133 drugs

Part D claims

7,462

Median for Physician Assistant: 241

Drug cost

$947,530

Median for Physician Assistant: $4,110

Branded share of claims

23.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 96 $110,603
Eliquis Apixaban Brand 109 $108,851
Mounjaro Tirzepatide Brand 84 $97,294
Ozempic Semaglutide Brand 73 $92,965
Xarelto Rivaroxaban Brand 67 $74,677
Trulicity Dulaglutide Brand 53 $70,466
Farxiga Dapagliflozin Propanediol Brand 61 $69,471
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 31 $42,623
Dupixent Pen Dupilumab Brand 11 $40,262
Linzess Linaclotide Brand 30 $28,361

The 10 drugs with the highest cost, of 133 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$123,579

Of which drugs: $4,795

Medicare patients

514

Average age 76

Services billed

3,633

208 women, 306 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 46%
Ischemic heart disease 27%
Chronic kidney disease 21%
Diabetes 19%
Osteoporosis 19%
Atrial fibrillation 14%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 34 146 $97

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISUNLA
  • Lilly USA, LLC $137
$137 — —
YUPELRI
  • Mylan Specialty L.P. $95
$95 — —
Leqembi
  • Eisai Inc. $85
$85 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $84
$84 38 —
JARDIANCE
  • Lilly USA, LLC $62
  • Boehringer Ingelheim Pharmaceuticals, Inc. $21
$83 96 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

330 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record